Anti-OPG (P25) Antibody |产品详情|进口试剂采购网

您好，欢迎来到拜力生物网站！请登录注册

我的订单 | 联系我们 | 在线客服QQ：3012681483 | 客服电话：400-968-7988 | 工作时间：08:30-17:30

主营产品： ELISA试剂盒、抗体、补体血清、兔补体、干扰素、小鼠测温仪、进口试剂、Quidel代理、Swant代理、PBL Assay Science代理

网站首页产品中心代理品牌新闻资讯资源中心关于我们

所在位置：首页 > 产品中心 > Antibodies > Antibodies产品

订购信息

上海拜力生物科技公司

Tel:400-968-7988 021-33779008

Anti-OPG (P25) Antibody

品牌：Antibodies

货号：

规格：50µl

货期：

应用：

咨询客服

立即购买加入购物车

Anti-OPG (P25) Antibody

商品详情参考文献相关资料

Overview

Name:	Anti-OPG (P25) Antibody See all OPG primary antibodies
Description:	Rabbit polyclonal antibody to OPG (P25)
Specificity:	OPG (P25) pAb detects endogenous levels of Osteoprotegerin protein.
Applications:	WB, IHC, IF
Reactivity:	Human, Mouse, Rat
Immunogen:	Synthetic peptide, corresponding to amino acids 1-50 of Human OPG.
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	Unconjugated
Molecular Weight:	~ 46 kDa
Purity:	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Product Form:	1 mg/ml in Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.2.

Target

Function:	Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Tissue Specificity:	Highly expressed in ***** lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
Involvement in Disease:	Paget disease of bone 5, juvenile-onset: An autosomal recessive, juvenile-onset form of Paget disease, a disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal ***** lamellar bone. PDB5 clinical manifestations include short stature, progressive long bone deformities, fractures, vertebral collapse, skull enlargement, and hyperostosis with progressive deafness.
Post-Translational Modification:	N-glycosylated. Contains sialic acid residues.
Cellular Location:	Secreted.
Database Links:	Entrez Gene: 4982?Human Entrez Gene: 18383?Mouse Entrez Gene: 25341?Rat Omim: 602643?Human SwissProt: O00300?Human SwissProt: O08712?Mouse SwissProt: O08727?Rat Unigene: 81791?Human Unigene: 15383?Mouse Unigene: 202973?Rat
Synonyms:	MGC29565 Antibody MGC93568 Antibody OCIF Antibody OPG Antibody Osteoclastogenesis inhibitory factor Antibody Osteoprotegerin Antibody PDB5 Antibody TNF receptor superfamily member 11b Antibody TNFRSF 11B Antibody TNFRSF11B Antibody TR 1 Antibody TR1 Antibody TR11B_HUMAN Antibody Tumor necrosis factor receptor superfamily member 11B Antibody
Information:	Target information shown above is from the UniProt Consortium.